Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients
PHASE2CompletedINTERVENTIONAL
Enrollment
70
Participants
Timeline
Start Date
January 1, 2016
Primary Completion Date
June 30, 2017
Study Completion Date
December 31, 2019
Conditions
Clinical ResponseToxicitySurvival
Interventions
DRUG
metronomic XELOX
DRUG
Classic XELOX
OTHER
Blood samples for pharmacological studies
All Listed Sponsors
lead
National Cancer Institute, Egypt
OTHER
NCT04425564 - Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter